NORTHERN TRUST CORP - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 106 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.

Quarter-by-quarter ownership
NORTHERN TRUST CORP ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$1,420,669
-8.7%
1,203,957
+9.1%
0.00%
Q2 2023$1,555,416
+337.4%
1,103,132
+365.3%
0.00%
Q1 2023$355,625
+36.0%
237,083
+6.1%
0.00%
Q4 2022$261,437
+3.7%
223,4500.0%0.00%
Q3 2022$252,000
-21.0%
223,450
+10.7%
0.00%
Q2 2022$319,000
-79.9%
201,775
-80.4%
0.00%
Q1 2022$1,587,000
-40.1%
1,030,809
-4.6%
0.00%
Q4 2021$2,648,000
-29.8%
1,080,924
-27.8%
0.00%
-100.0%
Q3 2021$3,774,000
-18.7%
1,497,627
-8.1%
0.00%0.0%
Q2 2021$4,641,000
+566.8%
1,628,749
+449.7%
0.00%
Q1 2021$696,000
+51.0%
296,293
+13.1%
0.00%
Q4 2020$461,000
+82.9%
262,029
-2.6%
0.00%
Q3 2020$252,000
+19.4%
269,056
+10.7%
0.00%
Q2 2020$211,000
-80.1%
243,135
-81.0%
0.00%
Q1 2020$1,062,000
+3.0%
1,282,556
+10.8%
0.00%
Q4 2019$1,031,000
-12.4%
1,157,701
-3.6%
0.00%
Q3 2019$1,177,0001,201,3590.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2022
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,005,379$85,694,0004.37%
Defender Capital, LLC. 4,798,270$12,707,0004.13%
Raffles Associates 93,590$236,0000.22%
Prescott General Partners LLC 1,851,851$4,667,0000.16%
DCF Advisers, LLC 87,000$219,0000.10%
Laidlaw Wealth Management LLC 104,841$264,0000.07%
Beirne Wealth Consulting Services, LLC 45,000$113,0000.06%
Strategic Wealth Investment Group, LLC 70,625$179,0000.05%
Fort Sheridan Advisors LLC 47,931$121,0000.04%
Sightline Wealth Advisors, LLC 14,958$38,0000.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders